DrugPatentWatch Database Preview
Alvogen Company Profile
What is the competitive landscape for ALVOGEN, and when can generic versions of ALVOGEN drugs launch?
ALVOGEN has forty-five approved drugs.
There is one US patent protecting ALVOGEN drugs.
Summary for Alvogen
| US Patents: | 1 |
| Tradenames: | 39 |
| Ingredients: | 36 |
| NDAs: | 45 |
| Patent Litigation for Alvogen: | See patent lawsuits for Alvogen |
Drugs and US Patents for Alvogen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alvogen Inc | PRIMAQUINE PHOSPHATE | primaquine phosphate | TABLET;ORAL | 203924-001 | Feb 3, 2014 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Alvogen Malta | NAPRELAN | naproxen sodium | TABLET, EXTENDED RELEASE;ORAL | 020353-002 | Jan 5, 1996 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ||||
| Alvogen Inc | ACETYLCYSTEINE | acetylcysteine | SOLUTION;INHALATION, ORAL | 204674-001 | Feb 11, 2014 | AN | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Alvogen Malta | SPECTAZOLE | econazole nitrate | CREAM;TOPICAL | 018751-001 | Dec 23, 1982 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Alvogen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alvogen Malta | ZESTORETIC | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019888-003 | Nov 18, 1993 | 4,374,829*PED | ➤ Sign Up |
| Alvogen | ADALAT CC | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 020198-003 | Apr 21, 1993 | 4,892,741 | ➤ Sign Up |
| Alvogen Malta | ZESTORETIC | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019888-001 | Sep 20, 1990 | 4,472,380 | ➤ Sign Up |
| Alvogen Malta | TENORETIC 50 | atenolol; chlorthalidone | TABLET;ORAL | 018760-002 | Jun 8, 1984 | 3,663,607 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for ALVOGEN drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 450 mg | ➤ Subscribe | 2013-02-28 |
International Patents for Alvogen Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2008038155 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Alvogen Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2011005 | Lithuania | ➤ Sign Up | PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126 |
| 00095 | Netherlands | ➤ Sign Up | PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419 |
| 80016 | Netherlands | ➤ Sign Up | PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606 |
| C/GB04/032 | United Kingdom | ➤ Sign Up | PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
